Movement Disorders

Maura McCarthy, head of corporate development at Skyhawk Therapeutics, provided comment on a new phase 1 study assessing SKY-0515, a small molecule candidate as a potential treatment for Huntington disease.

Daniel Claassen, MD, MS, emphasizes the utilization of social workers to reduce the psychosocial burden of HD on both the patient and their family.

An expert neurologist discusses the management of HD, highlighting pharmacologic vs nonpharmacologic treatment.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is ataxia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 8, 2023.

Catch up on any of the neurology news headlines you may have missed over the course of November 2023, compiled all into one place by the NeurologyLive® team.

A recent study showed the efficacy of multicompartment diffusion measures in distinguishing patients with Friedreich ataxia from controls, emphasizing the potential for these metrics in tracking disease expression and progression.

The neurology doctors discuss motor fluctuations and dyskinesia associated with Parkinson’s Disease.

Daniel Claassen, MD, MS, shares his approach to diagnosing patients with HD, as well as communicating with patients about the hereditary nature of the disease.

Daniel Claassen, MD, MS, provides an overview of the pathophysiology and genetic background of Huntington’s disease (HD), a neurodegenerative disorder.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Epilepsy Society.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 1, 2023.

PREDICT-PD, a low intensity and cost-efficient assessment, was able to estimate the occurrence of motor disturbances in the future, in particular sub-threshold parkinsonism and bradykinesia.

Jim Eubanks, PhD, national director of medical affairs at Octave, provided thoughts on the company’s $10 million grant from The Michael J. Fox Foundation for Parkinson’s Research and highlighted the importance of awareness for movement disorders like Parkinson disease.

The professor of neurology at the University of Toronto provided insight on several prominent targets in the brain for deep brain stimulation, including emerging ones that may not gain as much attention. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is general neurology.

Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 24, 2023.

Apart from the small pump system, which was preferred by the patients, the study found no clear advantage of levodopa-entacapone-carbidopa to levodopa-carbidopa intestinal gel.

In a phase 2 study, sodium oxybate showed a significant, albeit short-lived, reduction in voice symptoms for patients with alcohol-responsive essential tremor of voice.

The double-blind, placebo-controlled study is expected to include 9 patients aged 35-75 years old with MSA-parkinsonian type who will be randomized 2:1 to either investigational AB-1005 or sham surgery.

Here's some of what is coming soon to NeurologyLive® this week.